Prime Medicine (PRME) Receivables (2024 - 2025)
Prime Medicine's (PRME) quarterly Receivables came in at $4.6 million in Q4 2025, up 185.02% YoY from $1.6 million in Q4 2024, and up 3721.67% on a QoQ basis from $120000.0 in Q2 2025.
Powered by 
Analysis
Prime Medicine (PRME) Receivables (2024 - 2025) Analysis & Trends
Prime Medicine (PRME) has 2 years of Receivables data on file, last reported at $4.6 million in Q4 2025.
- Quarterly Receivables rose 185.02% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 185.02% YoY) and the FY2025 annual result came in at $4.6 million, up 185.02% from the prior year.
- Receivables grew to $4.6 million in Q4 2025, from $120000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $55.0 million in Q3 2024 to a low of $17000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Prime Medicine | 653.96 Mn | 653.96 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Sep 30, 2024 | 55.00 Mn |